congestive heart failure
Conditions
Interventions
Tolvaptan group: Add 7.5mg/day administration. If the effect is insufficient, to enable increased up to 15mg/day
Furosemide group: Add furosemide administration
Sponsors
Graduate School of Medical Sciences, Kumamoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Heart failure patients with volume overload despite the use of loop diuretics (Furosemide 20-80mg/day).
Exclusion criteria
Exclusion criteria: 1) Patients with decompensated HF in acute period 2) Patients with cardiac assist device 3) Patients with dehydration 4) Patients with severe hypotention or cardioganic shock 5) Patients with impaired consciousness 6) Patients who cannot feel thirst and are difficult to intake of fluid 7) Patient who is evaluated to be undesirable rapid decrease in circulating plasma volume 8) Patients who a history of hypersensitivity to tolvaptan 9) Patients with anuria, dialysis patient 10) Patients with severe aortic stenosis, mitral stenosis 11) Scheduled patients underwent coronary angioplasty within the study period, and patients with acute coronary syndrome 12) Hypertrophic obstructive cardiomyopathy 13) Patients with hypernatremia(serum Na+ >145 mEq/L) 14) Patients with hyperpotassemia(serum K+ >5.5 mEq/L) 15) Patient is willing to pregnant or potentially pregnant women, nursing mothers, pregnant 16) Patients with cancer 17) Patients considered not eligible for the study by the attending doctor due to other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in eGFR, Changes in serum sodium | — |
Secondary
| Measure | Time frame |
|---|---|
| Worsening Renal Function(WRF), leg edema, dyspnea, death due to heart failure and fatal arrhythmia(VT/VF), PRA, PAC, BNP, body weight, echocardiogram | — |
Countries
Japan
Contacts
Public ContactMegumi Yamamuro
Graduate School of Medical Sciences, Kumamoto University Cardiovascular medicine
Outcome results
None listed